• IBRITUMOMAB TIUXETAN chembl:CHEMBL1201606 ApprovedAntineoplastic

    Alternate Names:

    IDEC-Y2B8
    IDEC-129
    IDEC-Y2B8 IDEC-129
    ZEVALIN KIT-INDIUM-111
    IBRITUMOMAB TIUXETAN
    IDEC-IN2B8
    ZEVALIN
    IG GAMMA-2A CHAIN C REGION, MEMBRANE-BOUND FORM
    RADIOLABELED MURINE ANTI-CD20
    drugbank:00078
    chembl:CHEMBL1201606
    pubchem.compound:74890578
    rxcui:262323
    chemidplus:206181-63-7

    Drug Info:

    Drug Class antineoplastic agents
    Year of Approval 2002
    FDA Approval 2002
    Drug Class monoclonal antibody
    Drug Indications Antineoplastic Agents
    (1 More Sources)

    Publications:

    • Version: 01-August-2011

    Alternate Names:
    IBRITUMOMAB Primary Drug Name

    Drug Info:
    Year of Approval 2002
    Drug Class antineoplastic agents

    Publications:

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Antineoplastic Agents
    Drug Class monoclonal antibody
    FDA Approval 2002

    Publications:

    • Version: 2020.06.01

    Alternate Names:
    D01TVQ TTD Drug ID

    Drug Info:

    Publications:

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications: